2025 has been the best year for biotechs being acquired by pharma companies since 2019, with nearly $240 billion worth of ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's peak sales estimations makes this biotech stock attractive.

NDAA package revives stalled measures on US outbound investment and biotech, signalling Capitol Hill's hardened stance ...

Detailed price information for Amicus Therapeutics (FOLD-Q) from The Globe and Mail including charting and trades.

Startup investors this week demonstrated continued willingness to write big checks for promising companies in sought-after ...

The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain ...

The Trump administration may have softened its language on China to maintain a truce in their trade war, but Congress is ...

Just after market close on Monday, Dyne announced that it has launched an underwritten public offering of $300 million worth ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, ...